Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion is a commercial-stage healthcare technology company that uses AI-driven imaging technology to optimize clinical treatment of lower back and neck pain, and its recent issuance of a new US patent regarding pain assessment using MRS data adds to its significant portfolio of patents. The company is experiencing strong commercial momentum and has formed partnerships with multiple clinics and healthcare providers, which is reflected in its rising revenues. Despite some risks, including a recent increase in operating expenses, Aclarion has a strong balance sheet with over $20 million in cash, positioning it well for future growth and commercialization of its product.

Bears say

Aclarion is experiencing an expansion in share count which has resulted in a better-than-expected EPS for Q1 FY26. However, despite an 11% increase in revenue and higher Nociscan report volume, the company's operating expenses have also significantly increased due to investments in sales, R&D, and IR. The lack of forward guidance also raises concerns about the company's future profitability and growth potential.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.